Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.69 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.69 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.69 |
| ▸ | DPP4 | P27487 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.69 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.69 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.69 |
| ▸ | GAPDH | P04406 | 1/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.69 |
| ▸ | STAT6 | P42226 | 1/20 | 0.69 |
| ▸ | PI4KA | P42356 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.69 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.69 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.69 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18503540 | 1.00 | ADORA2A (0.69) | ADORA2AADORA2BSLC29A1DPP4MEN1 | |
| SCHEMBL27419960 | 1.00 | ADORA2A (0.69) | ADORA2AADORA2BSLC29A1DPP4MEN1 | |
| SCHEMBL15623876 | 1.00 | ADORA2A (0.69) | ADORA2AADORA2BSLC29A1DPP4MEN1 | |
| SCHEMBL3150637 | 1.00 | ADORA2A (0.69) | ADORA2AADORA2BSLC29A1DPP4MEN1 | |
| SCHEMBL29390532 | 1.00 | ADORA2A (0.69) | ADORA2AADORA2BSLC29A1DPP4MEN1 | |
| SCHEMBL157531 | 1.00 | ADORA2A (0.69) | ADORA2AADORA2BSLC29A1DPP4MEN1 | |
| SCHEMBL18486352 | 1.00 | ADORA2A (0.69) | ADORA2AADORA2BSLC29A1DPP4MEN1 | |
| SCHEMBL1996593 | 1.00 | ADORA2A (0.69) | ADORA2AADORA2BSLC29A1DPP4MEN1 | |
| SCHEMBL20579764 | 1.00 | ADORA2A (0.69) | ADORA2AADORA2BSLC29A1DPP4MEN1 | |
| SCHEMBL157530 | 1.00 | ADORA2A (0.69) | ADORA2AADORA2BSLC29A1DPP4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4634380-A1 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | ModernaTX, Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| EP-4565692-A2 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | ModernaTX, Inc. (US) | 2025-06-11 | — | — | EP | claimed |
| WO-2024129779-A1 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | MODERNATX, INC. (US) | 2024-06-20 | — | — | WO | claimed |
| WO-2024031087-A2 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | MODERNATX, INC. (US) | 2024-02-08 | — | — | WO | claimed |
| CN-117413065-A | Constructs, methods and uses for the preparation of circular RNAs | 上海环码生物医药有限公司 | 2024-01-16 | — | — | CN | claimed |
| CN-111744019-B | Mannose-based mRNA targeted delivery system and application thereof | 深圳瑞吉生物科技有限公司 | 2023-08-04 | — | — | CN | claimed |
| WO-2026107144-A1 | RNA SEQUENCE FOR EXPRESSING PROTEIN IN CARDIOMYOCYTES | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2026-05-21 | — | — | WO | disclosed |
| CN-122070366-A | Cyclic RNA compositions and methods | 欧纳医疗公司 | 2026-05-19 | — | — | CN | disclosed |
| WO-2026102302-A1 | POLYNUCLEOTIDES CONTAINING A MODIFIED 3'-REGION | MODERNATX, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4739778-A2 | RNA MOLECULE | Imperial College Innovations Limited (GB) | 2026-05-13 | — | — | EP | disclosed |
| CN-122029278-A | Constructs, methods and uses for the preparation of circular RNAs | 上海环码生物医药有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4728063-A1 | METHODS OF SIMULTANEOUSLY IDENTIFYING OR QUANTIFYING CAPPING AND TAILING MODIFICATIONS OF MESSENGER RNA | Sanofi Pasteur Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12595226-B2 | Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| WO-2022103839-A1 | RNA EDITING COMPOSITIONS AND USES THEREOF | SHAPE THERAPEUTICS INC. (US) | 2022-05-19 | — | — | WO | disclosed |
| CN-114381470-A | Artificial nucleic acid molecules | 库瑞瓦格股份公司 | 2022-04-22 | — | — | CN | disclosed |
| US-20220112494-A1 | IN VIVO GENE SILENCING BY CHEMICALLY MODIFIED AND STABLE siRNA | UNIVERSITY OF MASSACHUSETTS | 2022-04-14 | — | — | US | disclosed |
| US-11299734-B2 | RNA interference for the treatment of gain-of-function disorders | UNIVERSITY OF MASSACHUSETTS (US) | 2022-04-12 | — | — | US | disclosed |
| WO-2022066757-A1 | IMPROVED METHODS AND COMPOSITIONS FOR EXPRESSION OF NUCLEIC ACIDS IN CELLS | MYELOID THERAPEUTICS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| US-11279930-B2 | O-methyl rich fully stabilized oligonucleotides | UNIVERSITY OF MASSACHUSETTS (US) | 2022-03-22 | — | — | US | disclosed |
| CN-107406854-B | RNA-guided eradication of human JC virus and other polyomaviruses | 英联邦高等教育系统天普大学 | 2022-03-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112494-A1 | IN VIVO GENE SILENCING BY CHEMICALLY MODIFIED AND STABLE siRNA | SNRPE, AGO2, NSUN2 | ADORA2A 2178/4885ADORA2B 2505/4885SLC29A1 268/4885 |
| US-12595226-B2 | Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents | LNPK, PCTP, PLTP | ADORA2A 4176/4885ADORA2B 4089/4885SLC29A1 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.